Advancing Strategies for Proteolysis-Targeting Chimera Design.

Humans Proteolysis Drug Discovery Proteins / metabolism Antineoplastic Agents / therapeutic use Neoplasms / drug therapy Ubiquitin-Protein Ligases / metabolism

Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
23 02 2023
Historique:
pubmed: 15 2 2023
medline: 25 2 2023
entrez: 14 2 2023
Statut: ppublish

Résumé

Proteolysis-targeting chimeras (PROTACs) have shown great therapeutic potential by degrading various disease-causing proteins, particularly those related to tumors. Therefore, the introduction of PROTACs has ushered in a new chapter of antitumor drug development, marked by significant advances over recent years. Herein, we describe recent developments in PROTAC technology, focusing on design strategy, development workflow, and future outlooks. We also discuss potential opportunities and challenges for PROTAC research.

Identifiants

DOI: 10.1021/acs.jmedchem.2c01555 PMID: 36788245
pubmed: 36788245
doi: 10.1021/acs.jmedchem.2c01555
doi:

Substances chimiques

Proteins 0
Antineoplastic Agents 0
Ubiquitin-Protein Ligases EC 2.3.2.27

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2308-2329

Auteurs

Minglei Li (M)

School of Pharmacy and Pharmaceutical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117 Shandong, P. R. China.
ORCID: 0000-0002-8381-2455

Ying Zhi (Y)

School of Pharmacy and Pharmaceutical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117 Shandong, P. R. China.

Bo Liu (B)

School of Pharmacy and Pharmaceutical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117 Shandong, P. R. China.

Qingqiang Yao (Q)

School of Pharmacy and Pharmaceutical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117 Shandong, P. R. China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Advancing Strategies for Proteolysis-Targeting...
questionsmedicales.fr › Métabolisme › Protéolyse › Advancing Strategies for Proteolysis-Targeting...
questionsmedicales.fr › Techniques d'investigation › Développement de médicament › Découverte de médicament › Advancing Strategies for Proteolysis-Targeting...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Advancing Strategies for Proteolysis-Targeting...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Advancing Strategies for Proteolysis-Targeting...
questionsmedicales.fr › Tumeurs › Advancing Strategies for Proteolysis-Targeting...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Ligases › Ubiquitin-protein ligase complexes › Ubiquitin-protein ligases › Advancing Strategies for Proteolysis-Targeting...